Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key

Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key

Submitted by admin on July 5, 2018 - 7:42pm
Source: 
Fierce Biotech
News Tags: 
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
Headline: 
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
snippet: 

Gilead Sciences is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib in the next few weeks that could be an antidote for the biotech’s hepatitis C hangover.

Do Not Allow Advertisers to Use My Personal information